K. Clark-Langone

发表

Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients

Andreas Makris, Susan G. Hilsenbeck, Frederick L. Baehner, 2008, Breast Cancer Research and Treatment.

Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin.

Margarita Lopatin, Greg Yothers, Carl Millward, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Validation of a 12-gene colon cancer recurrence score (RS) in patients (pts) with stage II colon cancer (CC) from CALGB 9581.

R. Schilsky, M. Bertagnolli, P. Friedman, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of molecular and pathologic features of stage II and stage III colon cancer in four large studies conducted for development of the 12-gene colon cancer recurrence score.

D. Kerr, N. Wolmark, R. Gray, 2010 .

Validation of the 12-gene colon cancer recurrence score (RS) in NSABP C07 as a predictor of recurrence in stage II and III colon cancer patients treated with 5FU/LV (FU) and 5FU/LV+oxaliplatin (FU+Ox).

S. Paik, S. Shak, N. Wolmark, 2012 .

Liquid biopsy mutation panel for non-small cell lung cancer: analytical validation and clinical concordance.

C. Escriu, P. Tomasini, K. Clark-Langone, 2020, NPJ precision oncology.

Validation of the 12-gene colon cancer recurrence score as a predictor of recurrence risk in stage II and III rectal cancer patients.

H. Putter, S. Shak, P. Kuppen, 2014, Journal of the National Cancer Institute.

Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer.

D. Kerr, S. Shak, F. Baehner, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biomarker discovery for colon cancer using a 761 gene RT-PCR assay

M. Cronin, Chungyeul Kim, J. Baker, 2007, BMC Genomics.

Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581.

R. Schilsky, M. Bertagnolli, P. Friedman, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX® Colon Cancer Assay

D. Watson, K. Clark-Langone, C. Sangli, 2010, BMC Cancer.

Analytical validation of the Oncotype DX prostate cancer assay – a clinical RT-PCR assay optimized for prostate needle biopsies

D. Watson, C. Magi-Galluzzi, E. Klein, 2013, BMC Genomics.

Liquid biopsy mutation panel for non-small cell lung cancer: analytical validation and clinical concordance

A. Bergamaschi, F. Baehner, C. Escriu, 2020, npj Precision Oncology.

Analytical validation of the Oncotype DX prostate cancer assay – a clinical RT-PCR assay optimized for prostate needle biopsies

D. Watson, C. Magi-Galluzzi, E. Klein, 2013, BMC Genomics.

Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin.

S. Paik, S. Shak, J. Baker, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The 12-gene colon cancer assay validation and utility: Summary of clinical evidence.

S. Shak, M. Lopatin, K. Clark-Langone, 2014 .

Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer.

D. Kerr, S. Shak, F. Baehner, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.